Statins: The role in the treatment and prevention of alzheimer's neurodegeneration

Journal of Alzheimer's Disease

Volumn 27, Issue 1, 2011, Pages 1-10

  Pac Soo, Chen ^a,b   Lloyd, Dafydd G ^a   Vizcaychipi, Marcela P ^a   Ma, Daqing ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b WYCOMBE HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; cholesterol; inflammation; microglial activation; statin

Indexed keywords

ACETYL COENZYME A; AMYLOID PRECURSOR PROTEIN; ARF PROTEIN; ATORVASTATIN; BETA SECRETASE; BETA SECRETASE 1; CHOLESTEROL; FARNESYL DIPHOSPHATE; GAMMA INTERFERON; GAMMA SECRETASE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PHOP PROTEIN; PLACEBO; PROTEIN CDC42; RAB PROTEIN; RAC1 PROTEIN; RAS PROTEIN; RHO FACTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TAU PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM; CHOLESTEROL SYNTHESIS; COGNITION; DISEASE COURSE; DRUG BINDING; ENCEPHALITIS; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PAIRED HELICAL FILAMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION;

EID: 80155191187     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110524     Document Type: Review

References (118)

1. Simons M, Keller P, Dichgans J, Schulz J (2001) Cholesterol and Alzheimer's disease: is there a link? Neurology 57, 1089-1093. (Pubitemid 32880208)
2. Juva K, Sulkava R, Erkinjuntti T, Ylikoski R, Valvanne J, Tilvis R (1994) Staging the severity of dementia: comparison of clinical (CDR, DSM-III-R), functional (ADL, IADL) and cognitive (MMSE) scales. Acta Neurol Scand 90, 293-298. (Pubitemid 24321506)
3. Wolfson C, Wolfson DB, Asgharian M, M'Lan CE, Ostbye T, Rockwood K, Hogan DB (2001) A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 344, 1111-1116. (Pubitemid 32285231)
4. Department for Work and Pensions GB (2010) Number of future centenarians, http://statistics.dwp.gov.uk/asd/asd1/adhoc analysis/2010/Centenarians.pdf.
5. Ankri J, Poupard M (2003) [Prevalence and incidence of dementia among the very old. Review of the literature]. Rev Epidemiol Sante Publique 51, 349-360. (Pubitemid 37033682)
6. Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, Funkenstein HH, Evans DA (1995) Agespecific incidence of Alzheimer's disease in a community population. JAMA 273, 1354-1359.
7. Corrada M, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas C (2010) Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol 67, 114-121.
8. Sparks DL, Hunsaker JC, 3rd, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR (1990) Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 11, 601-607.
9. Kalback W, Esh C, Castaño E, Rahman A, Kokjohn T, Luehrs D, Sue L, Cisneros R, Gerber F, Richardson C, Bohrmann B, Walker D, Beach T, Roher A (2004) Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res 26, 525-539. (Pubitemid 38879235)
10. Mayeux R (2003) Epidemiology of neurodegeneration. Annu Rev Neurosci 26, 81-104. (Pubitemid 37064929)
11. Gr̈osgen S, Grimm M, Friess P, Hartmann T (2010) Role of amyloid beta in lipid homeostasis. Biochim Biophys Acta 1801, 966-974.
12. Strittmatter W, Roses A (1996) Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 19, 53-77. (Pubitemid 26080822)
13. Corder E, Saunders A, StrittmatterW, Schmechel D, Gaskell P, Small G, Roses A, Haines J, Pericak-Vance M (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923. (Pubitemid 23275809)
14. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Ruther E, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Gallacher J, Hull M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, van Duijn CM, Breteler MM, Ikram MA, Destefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alperovitch A, Lathrop M, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Bjornsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossu P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43, 429-435.
15. Wu CW, Liao PC, Lin C, Kuo CJ, Chen ST, Chen HI, Kuo YM (2003) Brain region-dependent increases in beta-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits. J Neural Transm 110, 641-649. (Pubitemid 36683517)
16. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-766. (Pubitemid 32267077)
17. Perlmutter LS, Barron E, Chui HC (1990) Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease. Neurosci Lett 119, 32-36. (Pubitemid 20349720)
18. Golde TE, Eckman CB, Younkin SG (2000) Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta 1502, 172-187. (Pubitemid 30433866)
19. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112. (Pubitemid 46432529)
20. Selkoe DJ (1994) Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 53, 438-447. (Pubitemid 24276802)
21. Hardy J, HigginsG(1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
22. Simons M, de Strooper B, Multhaup G, Tienari PJ, Dotti CG, Beyreuther K (1996) Amyloidogenic processing of the human amyloid precursor protein in primary cultures of rat hippocampal neurons. J Neurosci 16, 899-908. (Pubitemid 26140845)
23. Soscia SJ, Kirby JE,Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD (2010) The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PloS One 5, e9505.
24. Brown MS, Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340. (Pubitemid 27220877)
25. Dupree JL, Coetzee T, Blight A, Suzuki K, Popko B (1998) Myelin galactolipids are essential for proper node of Ranvier formation in the CNS. J Neurosci 18, 1642-1649. (Pubitemid 28103072)
26. Dietschy JM, Turley SD (2001) Cholesterol metabolism in the brain. Curr Opin Lipidol 12, 105-112. (Pubitemid 32242918)
27. Jurevics H, Morell P (1995) Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem 64, 895-901.
28. Koudinov AR, Koudinova NV (2001) Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 15, 1858-1860.
29. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354-1357. (Pubitemid 33063104)
30. Bjorkhem I, Lutjohann D, Diczfalusy U, Stahle L, Ahlborg G,Wahren J (1998) Cholesterol homeostasis in human brain: turnover of 24S- hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 39, 1594-1600. (Pubitemid 28377923)
31. Simons K, Ikonen E (1997) Functional rafts in cell membranes. Nature 387, 569-572. (Pubitemid 27248754)
32. Brown DA, London E (1998) Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 14, 111-136. (Pubitemid 29001451)
33. Korade Z, Kenworthy AK (2008) Lipid rafts, cholesterol, and the brain. Neuropharmacology 55, 1265-1273.
34. Reid PC, Urano Y, Kodama T, Hamakubo T (2007) Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 11, 383-392. (Pubitemid 47153452)
35. Xiong H, Callaghan D, Jones A,Walker DG, Lue LF, Beach TG, Sue LI, Woulfe J, Xu H, Stanimirovic DB, Zhang W (2008) Cholesterol retention in Alzheimer's brain is responsible for high beta-and gamma-secretase activities and Abeta production. Neurobiol Dis 29, 422-437.
36. Adibhatla RM, Hatcher JF (2008) Altered lipid metabolism in brain injury and disorders. Subcell Biochem 49, 241-268.
37. Kolsch H, Heun R, Jessen F, Popp J, Hentschel F, Maier W, Lutjohann D (2010) Alterations of cholesterol precursor levels in Alzheimer's disease. Biochim Biophys Acta 1801, 945-950.
38. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A (1998) Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17, 14-20. (Pubitemid 28153361)
39. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M (2007) Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 68, 751-756. (Pubitemid 46667900)
40. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R,Wolfson C, McDowell I (2002) Use of lipidlowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59, 223-227. (Pubitemid 34240938)
41. Vetrivel KS, Thinakaran G (2010) Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim Biophys Acta 1801, 860-867.
42. Guardia-Laguarta C, Coma M, Pera M, Clarimon J, Sereno L, Agullo JM, Molina-Porcel L, Gallardo E, Deng A, Berezovska O, Hyman BT, Blesa R, Gomez-Isla T, LleoA(2009) Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface. J Neurochem 110, 220-230.
43. Hur JW, Behbahani H, Aoki H, Franberg J, Winblad B, Frykman S, Tjernberg L (2008) Active gamma-secretase is localized to detergent-resistant membranes in human brain. FEBS J 275, 1174-1187. (Pubitemid 351342213)
44. Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ (2003) Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 100, 11735-11740. (Pubitemid 37206004)
45. Riddell DR, Christie G, Hussain I, Dingwall C (2001) Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol 11, 1288-1293. (Pubitemid 32774087)
46. Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160, 113-123. (Pubitemid 36091721)
47. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421. (Pubitemid 36937044)
48. Parodi J, Sepulveda FJ, Roa J, Opazo C, Inestrosa NC, AguayoLG(2010) Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J Biol Chem 285, 2506-2514.
49. Sepulveda FJ, Parodi J, Peoples RW, Opazo C, Aguayo LG (2010) Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One 5, e11820.
50. McGeer PL, Itagaki S, Tago H, McGeer EG (1987) Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 79, 195-200. (Pubitemid 17144469)
51. Salminen A, Ojala J, Suuronen T, Kaarniranta K, Kauppinen A(2008) Amyloid-beta oligomers set fire to inflammasomes and induce Alzheimer's pathology. J Cell MolMed12, 2255-2262.
52. Guo JP, Arai T, Miklossy J, McGeer PL (2006) Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci USA 103, 1953-1958. (Pubitemid 43228799)
53. Iqbal K, Grundke-Iqbal I (2008) Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 12, 38-55. (Pubitemid 351436349)
54. Gendron TF, Petrucelli L (2009) The role of tau in neurodegeneration. Mol Neurodegene 4, 13.
55. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663-672. (Pubitemid 47283144)
56. Glass C, Saijo K, Winner B, Marchetto M, Gage F (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934.
57. El Khoury J, Luster AD (2008) Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci 29, 626-632.
58. Maccioni RB, Rojo LE, Fernandez JA, Kuljis RO (2009) The role of neuroimmunomodulation in Alzheimer's disease. Ann N Y Acad Sci 1153, 240-246.
59. Heneka MT, O'Banion MK, Terwel D, Kummer MP (2010) Neuroinflammatory processes in Alzheimer's disease. J Neural Transm 117, 919-947.
60. Jana M, Palencia CA, Pahan K (2008) Fibrillar amyloidbeta peptides activate microglia via TLR2: implications for Alzheimer's disease. J Immunol 181, 7254-7262.
61. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421. (Pubitemid 30349107)
62. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE (2009) CD14 and toll-like receptors 2 and 4 are required for fibrillarA{beta}-stimulated microglial activation. J Neurosci 29, 11982-11992.
63. Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, Esler WP, Maggio JE, Mantyh PW (1998) Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 18, 2161-2173. (Pubitemid 28141421)
64. Ramasamy R, Yan SF, Schmidt AM (2009) RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol 86, 505-512.
65. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9, 857-865.
66. Kanneganti TD, Lamkanfi M, Nunez G (2007) Intracellular NOD-like receptors in host defense and disease. Immunity 27, 549-559. (Pubitemid 47615512)
67. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, Zubair AC, Dickson D, Golde TE, Das P (2010) Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J 24, 548-559.
68. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE (2009) Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci 29, 4252-4262.
69. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J (2003) Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 9, 453-457. (Pubitemid 36460080)
70. Combs CK, Karlo JC, Kao SC, Landreth GE (2001) beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 21, 1179-1188. (Pubitemid 32128763)
71. Floden AM, Combs CK (2006) Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J Neurosci 26, 4644-4648. (Pubitemid 44315365)
72. Sondag CM, Dhawan G, Combs CK (2009) Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J Neuroinflammation 6, 1.
73. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23, 9796-9804. (Pubitemid 37371592)
74. Rossner S, Lange-Dohna C, Zeitschel U, Perez-Polo JR (2005) Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. J Neurochem 92, 226-234. (Pubitemid 40194014)
75. Hartlage-Rubsamen M, Zeitschel U, Apelt J, Gartner U, Franke H, Stahl T, Gunther A, Schliebs R, Penkowa M, Bigl V, Rossner S (2003) Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulusdependent. Glia 41, 169-179. (Pubitemid 36262194)
76. Hong HS, Hwang EM, Sim HJ, Cho HJ, Boo JH, Oh SS, Kim SU, Mook-Jung I (2003) Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. Biochem Biophys Res Commun 307, 922-927. (Pubitemid 36871661)
77. Leuba G, Wernli G, Vernay A, Kraftsik R, Mohajeri MH, Saini KD (2005) Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease. Dement Geriatr Cogn Disord 19, 171-183. (Pubitemid 40522804)
78. De Pietri Tonelli D, Mihailovich M, Di Cesare A, Codazzi F, Grohovaz F, Zacchetti D (2004) Translational regulation of BACE-1 expression in neuronal and non-neuronal cells. Nucleic Acids Res 32, 1808-1817. (Pubitemid 38832726)
79. Buhaescu I, Izzedine H (2007) Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40, 575-584. (Pubitemid 46829082)
80. Takai Y, Sasaki T, Matozaki T (2001) Small GTP-binding proteins. Physiol Rev 81, 153-208. (Pubitemid 32098004)
81. Macara I, Lounsbury K, Richards S, McKiernan C, Bar-Sagi D (1996) The Ras superfamily of GTPases. FASEB J 10, 625-630. (Pubitemid 26141173)
82. Montaner S, Perona R, Saniger L, Lacal J (1998) Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J Biol Chem 273, 12779-12785. (Pubitemid 28246832)
83. Smale S (2010) Selective transcription in response to an inflammatory stimulus. Cell 140, 833-844.
84. Sen R, Baltimore D (1986) Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 47, 921-928. (Pubitemid 17005065)
85. Perona R, Montaner S, Saniger L, Śanchez-Ṕerez I, Bravo R, Lacal J (1997) Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 11, 463-475. (Pubitemid 27097645)
86. Williams L, Lali F, Willetts K, Balague C, Godessart N, Brennan F, Feldmann M, Foxwell B (2008) Rac mediates TNF-induced cytokine production via modulation of NFkappaB. Mol Immunol 45, 2446-2454.
87. Townsend K, Shytle D, Bai Y, San N, Zeng J, Freeman M, Mori T, Fernandez F, Morgan D, Sanberg P, Tan J (2004) Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J Neurosci Res 78, 167-176. (Pubitemid 39313788)
88. Clarke R, Lyons A, O'Connell F, Deighan B, Barry C, Anyakoha N, Nicolaou A, Lynch M (2008) A pivotal role for interleukin-4 in atorvastatin-associated neuroprotection in rat brain. J Biol Chem 283, 1808-1817.
89. Lindberg C, Crisby M, Winblad B, Schultzberg M (2005) Effects of statins on microglia. J Neurosci Res 82, 10-19. (Pubitemid 41604793)
90. Cordle A, Landreth G (2005) 3-Hydroxy-3-methylglutarylcoenzyme A reductase inhibitors attenuate beta-amyloidinduced microglial inflammatory responses. J Neurosci 25, 299-307. (Pubitemid 40105600)
91. Li W, Cui Y, Kushner S, Brown R, Jentsch J, Frankland P, Cannon T, Silva A (2005) The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 15, 1961-1967. (Pubitemid 41566145)
92. Ḧoglund K, Blennow K (2007) Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease. CNS Drugs 21, 449-462. (Pubitemid 46849181)
93. Kurinami H, Sato N, Shinohara M, Takeuchi D, Takeda S, Shimamura M, Ogihara T, Morishita R (2008) Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model. Int J Mol Med 21, 531-537.
94. Massaro M, Zampolli A, Scoditti E, Carluccio M, Storelli C, Distante A, De Caterina R (2010) Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc Res 86, 311-320.
95. Infante-Duarte C,Waiczies S,Wuerfel J, Zipp F (2008) New developments in understanding and treating neuroinflammation. J Mol Med 86, 975-985.
96. van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL (2009) Statins: mechanisms of neuroprotection. Prog Neurobiol 88, 64-75.
97. Kandiah N, Feldman HH (2009) Therapeutic potential of statins in Alzheimer's disease. J Neurol Sci 283, 230-234.
98. BarresB(2008) The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60, 430-440.
99. Adamson P, Greenwood J (2003) How do statins control neuroinflammation? Inflamm Res 52, 399-403. (Pubitemid 37260425)
100. Pahan K, Sheikh FG, Namboodiri AM, Singh I (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100, 2671-2679. (Pubitemid 28007534)
101. Li B, Mahmood A, Lu D, Wu H, Xiong Y, Qu C, Chopp M (2009) Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1beta level after traumatic brain injury. Neurosurgery 65, 179-185; discussion 185-176.
102. Zhou Y, Suram A, Venugopal C, Prakasam A, Lin S, Su Y, Li B, Paul SM, Sambamurti K (2008) Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of Abeta and APP-CTFgamma. FASEB J 22, 47-54.
103. Ostrowski SM,Wilkinson BL, Golde TE, LandrethG(2007) Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem 282, 26832-26844. (Pubitemid 47501902)
104. Cole SL, Vassar R (2006) Isoprenoids and Alzheimer's disease: a complex relationship. Neurobiol Dis 22, 209-222.
105. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P (2010) Statins for the treatment of dementia. Cochrane Database Syst Rev, CD007514.
106. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80, 13-17.
107. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57, 1439-1443.
108. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD (2008) Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71, 344-350.
109. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J,Wormstall H, HartmannT, Schulz JB (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52, 346-350. (Pubitemid 35001502)
110. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH (2005) Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 62, 1047-1051. (Pubitemid 41043724)
111. Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F (2010) Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis 21, 95-102.
112. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC (2005) Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62, 217-224. (Pubitemid 40189139)
113. Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, Bowen JD, Schellenberg GD, Crane PK, Breitner JC, Larson EB (2010) Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc 58, 1311-1317.
114. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22.
115. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623-1630. (Pubitemid 35379733)
116. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74, 956-964.
117. Parale GP, Baheti NN, Kulkarni PM, Panchal NV (2006) Effects of atorvastatin on higher functions. Eur J Clin Pharmacol 62, 259-265.
118. Sparks L (2009) Statins and cognitive function. J Neurol Neurosurg Psychiatry 80, 1-2.